Kymera Therapeutics presents preclinical data for KT-621

Kymera Therapeutics (KYMR) announced the presentation of additional preclinical data for KT-621, its potent, selective, oral STAT6 degrader and the first STAT6 targeted medicine to enter clinical development. The new asthma efficacy mouse model data showed both prevention of disease progression as well as reversal of established disease, building upon the compelling preclinical characterization of KT-621 as a potential once daily, oral treatment for asthma and other Th2 allergic and atopic diseases. These data were presented at the American Thoracic Society International Conference being held May 16-21, 2025, in San Francisco, CA. Additionally, Jared Gollob, CMO, was featured in an oral showcase presentation as part of the ATS Respiratory Innovation Summit discussing the Company’s industry-leading oral immunology portfolio, including the KT-621 program. The Company previously demonstrated that KT-621 prevents disease progression in the prophylactic intranasal house dust mite-induced model in IL-4/IL-4RA humanized mice. KT-621 robustly inhibited all the tested cytokines, chemokines, cell infiltrates, and lung remodeling involved in Th2 inflammation in asthma to an extent comparable or superior to an IL-4Ralpha saturating dose of the injectable IL-4Ralpha antibody, dupilumab, included in the same study. New data shared at ATS show that in the HDM-induced chronic mouse model with a therapeutic treatment regimen, KT-621 administered orally after disease establishment demonstrated comparable or superior activity to dupilumab in blocking Th2 inflammation. The Company also shared new histology data from the therapeutic efficacy model showing amelioration of lung remodeling, including goblet cell metaplasia and MUC5AC mRNA expression, after low daily oral doses of KT-621 that was superior to dupilumab. Overall, the preclinical data shared to date demonstrate the best-in-pathway potential of KT-621 for the treatment of Th2 allergic and atopic diseases given its dupilumab-like activity profile and the convenience of an oral pill. The Company has completed the Phase 1 healthy volunteer trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of KT-621 compared to placebo. In June 2025, Kymera will host a webcast to disclose the complete KT-621 Phase 1 healthy volunteer SAD/MAD data, which will include STAT6 degradation, safety and additional biomarker results. Additionally, the KT-621 BroADen Phase 1b trial in moderate to severe AD patients is ongoing, with data expected to be reported in the fourth quarter of 2025. Two parallel Phase 2b trials in AD and asthma are planned to start in 4Q25 and 1Q26, respectively.